There is no experience of the use of Circadin® in patients with liver impairment1. The metabolism of melatonin is reduced in people with hepatic impairment and these individuals demonstrate markedly elevated endogenous melatonin levels during daytime hours due to decreased clearance1. Therefore, Circadin® is not recommended for use in patients with hepatic impairment1.
The effect of any stage of renal insufficiency on melatonin pharmacokinetics has not been studied1. Caution should be used when melatonin is administered to such patients1.
The effect of any stage of renal insufficiency on melatonin pharmacokinetics has not been studied1. Caution should be used when melatonin is administered to such patients1.
Posted in: Drug safety